

Use, in cosmetic preparations, of prostaglandin EP-3 receptor agonists to attenuate, reduce or stop the growth of head hair and other hairs.

5 The present invention relates to use of prostaglandin EP-3 receptor agonists to attenuate, reduce or stop the growth of head hair and other hairs, in cosmetic or dermatological preparations, and to the cosmetic or dermatological treatment process using these
10 compositions.

It appears to be important in many uses such as depilation, to combat hirsutism and unwanted hairs or to obtain a bald head to have available compounds capable of
15 preparing compositions for attenuating, reducing or stopping the growth of keratin materials.

Patent WO 96/09806 by Handelsman describes compositions for reducing hair growth, containing a sufficient amount
20 of protein kinase C inhibitor such as verapamil, thioridazine, curcumin, etc.

Moreover, it is known that sulprostone is a prostaglandin EP-3 receptor agonist in document "VII. International
25 Union of Pharmacology Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and Their Subtypes" by Coleman et al., Pharmacological Reviews, 1994, Vol 46. The said document mentions that prostaglandin receptors induce a reduction
30 in the level of cAMP. The said document also points out that prostaglandin EP-3 receptor agonists have been used as gastric antisection agents in the treatment of gastric ulcers.

35 The action of sulprostone as a prostaglandin EP-3 receptor agonist is also mentioned in the document

"Growth regulation of primary human keratinocytes by prostaglandin E receptor EP-2 and EP-3 subtypes" by Konger et al., (Biochimica et Biophysica Acta 1401, 1998, 221-224). The said document reveals that cAMP is a positive signal for the growth of epidermal keratinocytes, but points out that the mechanism of action of the prostaglandins and the repercussions on the level of cAMP are poorly understood. The said document also teaches that prostaglandin receptors are thought to be involved in regulating epithelial cell growth.

Nevertheless, it is well known that the programmes of differentiation of the keratinocytes of the epidermis and of hair follicles are clearly different. Thus, it is known that differentiation markers such as keratins K1 and K10 are not expressed in hair follicles and in particular in the outer sheath (Lenoir et al., 1988, *Dev. Biol.* 130: 610-620); that trichohyalin is expressed in hair follicles, in particular in the inner sheath but not in the epidermis (O'Guin et al., 1992, *J. Invest. Dermatol.* 98: 24-32); and that type 1 cyclooxygenase is not expressed in the keratinocytes of hair follicles but is expressed in the epidermis (Michelet et al., 1997, *J. Invest. Dermatol.* 108: 205-209).

Furthermore, it is known that the keratinocytes of the epidermis and of hair follicles behave differently in response to the same pharmacological agent. Thus, it is known that, in vivo, treating the epidermis with retinoic acid induces hyperplasia and spongiosis (Griffiths et al., 1993, *J. Invest. Dermatol.* 101: 325-328) whereas treating the scalp induces a loss of hair (Berth-Jones et al., 1990, *Br. J. Dermatol.* 122: 751-755), and that, in vitro, retinoic acid, depending on the dose used, promotes or reduces the differentiation of the epidermis (Asselineau et al., 1989, *Dev. Biol.* 133: 32-335), while

5

10

15

20

25

30

35

of prostaglandin EP-3 receptor agonists to attenuate, reduce or stop the growth of head hair and other hairs. These agonists are also capable of increasing the loss of head hair and other hairs.

5

Another subject of the invention consists in using prostaglandin EP-3 receptor agonists to prepare a cosmetic composition.

10 Another subject of the invention consists of the cosmetic process for treating head hair and other hairs using such a composition.

15 Other subjects of the invention will become apparent on reading the description and the examples which follow.

The main subject of the present invention is the use of at least one prostaglandin EP-3 receptor agonist in accordance with the invention as a cosmetic or
20 dermatological agent to attenuate, reduce or stop the growth of head hair and other hairs.

Prostaglandins are biological effectors derived from polyunsaturated fatty acids such as, for example,
25 arachidonic acid for PGA_2 , PGE_2 , $\text{PGF}_{2\alpha}$ and TXA_2 , or from dihomo- γ -linolenic acid for PGE_1 . Prostaglandins are involved in many physiological regulation phenomena.

30 An agonist is a compound which binds to a receptor and which induces a biological response similar to that obtained with the natural ligand which activates this response.

35 These agonists are capable of attenuating, reducing or stopping the growth of head hair and other hairs and/or of increasing the loss of head hair and other hairs.

The term "other hairs" also means the eyelashes, the eyebrows and all hairs in general.

5⁶ The preferred compounds are chosen more particularly from sulprostone, the compound TEI 3356, the compound M&B-28767 and prostaglandin PGE1.

10 These agonists are mentioned in the document "Prostanoid Receptors: Structures, Properties, and Functions" by Shuh Narumya et al., Physiological Review, 1999, 1203-1204.

15 The compound TEI 3356 is described in the document Negishi M. et al., 1994, "TEI-3356 a highly selective agonist for the prostaglandin EP3 receptor" Prostaglandins, 48, 275-283.

20 Another subject of the present invention is the use of a prostaglandin EP-3 receptor agonist in or for the preparation of a cosmetic or dermatological composition for topical application, for attenuating, reducing or stopping the growth of head hair and other hairs.

25 This cosmetic composition may contain from 0.001% to 10% and preferably from 0.1% to 5% of agonists by weight relative to the weight of the composition.

30 In accordance with the invention, the compositions may also contain prostaglandin EP-2 and EP-4 receptor antagonists such as the compounds AH6809 and AH23848B described in the article "Identification of prostaglandin E receptor "EP-2" cloned from mastocytoma cells as EP4 subtype", FEBS Lett, 364, 339-341, 1995, in order to increase the effect of losing head hair and other hairs.

35 The cosmetically or dermatologically acceptable medium for the compositions according to the invention consists

more particularly of water and optionally of cosmetically acceptable organic solvent.

5 The organic solvents may represent from 5% to 98% of the total weight of the composition. They may be chosen from the group consisting of hydrophilic organic solvents, lipophilic organic solvents and amphiphilic solvents, or mixtures thereof.

10 Thus, the composition may also contain a cosmetically acceptable medium consisting of water or water and at least one organic solvent chosen from the group consisting of hydrophilic organic solvents, lipophilic organic solvents and amphiphilic solvents, or mixtures
15 thereof.

Among the hydrophilic organic solvents which may be mentioned, for example, are linear or branched lower monoalcohols containing from 1 to 8 carbon atoms, for
20 instance ethanol, propanol, butanol, isopropanol, isobutanol; optionally oxyethylenated polyethylene glycols; polyols such as propylene glycol, isoprene glycol, butylene glycol, glycerol or sorbitol and its derivatives; monoalkyl or dialkyl isosorbides in which
25 the alkyl groups contain from 1 to 5 carbon atoms, for instance dimethyl isosorbide; glycol ethers, for instance diethylene glycol monomethyl or monoethyl ether and polypropylene glycol ethers, for instance dipropylene glycol methyl ether.

30 Amphiphilic organic solvents which may be mentioned are polyols such as propylene glycol (PPG) derivatives, such as fatty acid esters of polypropylene glycol, PPG ethers of fatty alcohols, for instance PPG-23 oleyl ether, and
35 PPG-36 oleate.

Lipophilic organic solvents which may be mentioned, for example, are fatty esters such as diisopropyl adipate, dioctyl adipate and alkyl benzoates.

- 5 The preferred organic solvents are chosen from the group consisting of monofunctional or polyfunctional alcohols, optionally oxyethylenated polyethylene glycols, polypropylene glycol esters, sorbitol and its derivatives, dialkyl isosorbides, glycol ethers, 10 polypropylene glycol ethers and fatty esters.

- 15 In order for the cosmetic compositions of the invention to be more pleasant to use (milder on application, more nourishing and more emollient), it is possible to add a fatty phase to the medium for these compositions.

The fatty phase preferably represents from 0% to 50% of the total weight of the composition.

- 20 This fatty phase may comprise one or more oils preferably chosen from the group consisting of:

- volatile or non-volatile, linear, branched or cyclic, organomodified or unmodified, water-soluble or liposoluble silicones,
- 25 - mineral oils such as liquid paraffin and liquid petroleum jelly,
- oils of animal origin such as perhydrosqualene,
- oils of plant origin such as sweet almond oil, avocado oil, castor oil, olive oil, jojoba oil, sesame oil, groundnut oil, macadamia oil, grapeseed oil, 30 rapeseed oil or coconut oil,
- synthetic oils such as purcellin oil and isoparaffins,
- fluoro oils and perfluoro oils,
- 35 - fatty acid esters such as purcellin oil.

It may also comprise as fatty substances one or more fatty alcohols, fatty acids (ferric acid) or waxes (paraffin, polyethylene wax, carnauba wax or beeswax).

5 The composition may also additionally contain at least one additive chosen from the group consisting of conventional hydrophilic or lipophilic gelling agents and/or thickeners; hydrophilic or lipophilic active agents; preserving agents; antioxidants; fragrances; 10 emulsifiers; moisturizers; pigmenting agents; depigmenting agents; keratolytic agents; vitamins; emollients; sequestering agents; surfactants; polymers; acidifying or basifying agents; fillers; free-radical scavengers; ceramides; sunscreens; insect repellents; 15 slimming agents; colorants; bactericides; anti-dandruff agents.

The amounts of these various adjuvants are those used conventionally in the fields under consideration.

20 Needless to say, a person skilled in the art will take care to select the optional compound(s) to be added to the composition according to the invention such that the advantageous properties intrinsically associated with the 25 composition in accordance with the invention are not, or are not substantially, adversely affected by the addition envisaged.

The compositions according to the invention may be in any 30 presentation form normally used for topical application, in particular in the form of an aqueous, aqueous-alcoholic or oily solution, an oil-in-water or water-in-oil or multiple emulsion, an aqueous or oily gel, a liquid, pasty or solid anhydrous product or a dispersion 35 of oil in an aqueous phase with the aid of spherules, these spherules possibly being polymer nanoparticles such

as nanospheres and nanocapsules, or better still lipid vesicles of ionic and/or nonionic type.

5 The compositions may have the appearance of a white or coloured cream, an ointment, a milk, a lotion, a serum, a paste, a mousse or a solid.

They may optionally be applied to the skin in the form of an aerosol.

10

They may also be in solid form, and for example in the form of a stick. They may be used as care products and/or as make-up products.

15 The composition may have a pH of between 3 and 8.

Another subject of the present invention consists of a cosmetic or dermatological treatment process for attenuating, reducing or stopping the growth of head hair
20 and other hairs, which consists in applying to the head hair and/or other hairs a cosmetically or dermatologically effective amount of prostaglandin EP-3 receptor agonists.

25 According to another subject of the invention, the cosmetic or dermatological treatment process for attenuating, reducing or stopping the growth of head hair and other hairs also consists in applying to the head hair and/or other hairs a cosmetic or dermatological
30 composition as defined.

The examples which follow are intended to illustrate the invention without, however, being limiting in nature:

EXAMPLES OF LOTIONS FOR PREVENTING HAIR GROWTH

Example I:

5	<u>Sulprostone</u>	0.3 g
	Propylene glycol	20 g
	95° ethanol	30 g
	Water	qs 100 g

10 This lotion is applied daily at a rate of 10 ml to the scalp, for 2 to 3 months. A marked reduction in the daily growth of head hair and other hairs is then observed.

Example II:

15	<u>TEI 3356</u>	0.15 g
	Polyglyceryl 3-hydroxylauryl ether	26 g A.M.
	Hydroxypropylcellulose sold under the	
	name Klucell G by the company Hercules	2 g
20	Preserving agent	qs
	95° ethanol	50 g
	Water	qs 100 g

25 This lotion is used daily at a rate of 15 g per head of hair, with an exposure time of about one minute, for a period of 4 months. An appreciable reduction in the daily growth of the hair is then observed.

Example III:

30	<u>M&B-28767</u>	0.03 g
	Propylene glycol	20 g
	95° ethanol	30 g
	Water	qs 100 g

35

This lotion is applied daily at a rate of 10 ml to the scalp, for 2 to 3 months. A marked reduction in the daily growth of head hair and other hairs is then observed.

5 **Example IV:**

	Prostaglandin PGE1	0.015 g
	Polyglyceryl 3-hydroxylauryl ether	26 g A.M.
	Hydroxypropylcellulose sold under the	
10	name Klucell G by the company Hercules	2 g
	Preserving agent	qs
	AH23848B	1 g
	95° ethanol	50 g
	Water	qs 100 g

15

This lotion is used daily at a rate of 15 g per head of hair, with an exposure time of about one minute, for a period of 4 months. An appreciable reduction in the daily growth of the hair is then observed.

20

EXPERIMENT:

In order to study the behaviour of hair follicles in the presence of a prostaglandin EP-3 receptor agonist, the Applicant used the "surviving hair" method from L'Oréal Patent FR 9508465.

From a scalp biopsy, a fairly thin strip of scalp was isolated using a scalpel. With microtweezers, the adipose tissue around the follicles was removed, while taking care not to damage the hair bulb. Under a microscope, the follicle was cut away using a scalpel to separate it from its epidermal and dermal environment.

35

5. The other fragments were placed in the same culture medium in the presence of a prostaglandin EP-3 receptor agonist: sulprostone, compound TEI3356, compound M&B-28767, prostaglandin PGE1.

10 The fragments in the presence of the agonists thus maintained in histoculture shorten in a significantly greater manner in comparison with the agonist-free control fragment.